X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs STRIDES SHASUN LTD - Comparison Results

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA STRIDES SHASUN LTD AJANTA PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 20.1 13.9 145.2% View Chart
P/BV x 8.7 1.9 464.2% View Chart
Dividend Yield % 0.7 0.6 124.2%  

Financials

 AJANTA PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
STRIDES SHASUN LTD
Mar-16
AJANTA PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,7201,413 121.8%   
Low Rs1,103848 130.1%   
Sales per share (Unadj.) Rs194.6353.3 55.1%  
Earnings per share (Unadj.) Rs45.223.4 193.4%  
Cash flow per share (Unadj.) Rs50.341.0 122.7%  
Dividends per share (Unadj.) Rs8.005.00 160.0%  
Dividend yield (eoy) %0.60.4 128.1%  
Book value per share (Unadj.) Rs132.0320.4 41.2%  
Shares outstanding (eoy) m88.7789.35 99.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.33.2 226.7%   
Avg P/E ratio x31.248.3 64.6%  
P/CF ratio (eoy) x28.127.6 101.8%  
Price / Book Value ratio x10.73.5 303.1%  
Dividend payout %17.721.4 82.7%   
Avg Mkt Cap Rs m125,299100,988 124.1%   
No. of employees `000NA4.7 0.0%   
Total wages/salary Rs m2,5704,988 51.5%   
Avg. sales/employee Rs ThNM6,730.0-  
Avg. wages/employee Rs ThNM1,063.6-  
Avg. net profit/employee Rs ThNM445.5-  
INCOME DATA
Net Sales Rs m17,27531,564 54.7%  
Other income Rs m1661,212 13.7%   
Total revenues Rs m17,44232,776 53.2%   
Gross profit Rs m5,8075,213 111.4%  
Depreciation Rs m4511,573 28.6%   
Interest Rs m491,803 2.7%   
Profit before tax Rs m5,4743,049 179.5%   
Minority Interest Rs m0127 0.0%   
Prior Period Items Rs m0-27 0.0%   
Extraordinary Inc (Exp) Rs m0-371 0.0%   
Tax Rs m1,460689 212.0%   
Profit after tax Rs m4,0142,089 192.1%  
Gross profit margin %33.616.5 203.5%  
Effective tax rate %26.722.6 118.1%   
Net profit margin %23.26.6 351.0%  
BALANCE SHEET DATA
Current assets Rs m7,63935,949 21.2%   
Current liabilities Rs m2,71519,402 14.0%   
Net working cap to sales %28.552.4 54.4%  
Current ratio x2.81.9 151.9%  
Inventory Days Days4371 61.0%  
Debtors Days Days79127 62.0%  
Net fixed assets Rs m6,91434,478 20.1%   
Share capital Rs m177894 19.8%   
"Free" reserves Rs m11,44222,601 50.6%   
Net worth Rs m11,72128,632 40.9%   
Long term debt Rs m14927,455 0.5%   
Total assets Rs m14,81476,591 19.3%  
Interest coverage x112.92.7 4,196.9%   
Debt to equity ratio x01.0 1.3%  
Sales to assets ratio x1.20.4 283.0%   
Return on assets %27.45.1 539.6%  
Return on equity %34.27.3 469.3%  
Return on capital %46.58.2 569.7%  
Exports to sales %55.148.1 114.6%   
Imports to sales %6.014.5 41.5%   
Exports (fob) Rs m9,52715,192 62.7%   
Imports (cif) Rs m1,0384,565 22.7%   
Fx inflow Rs m10,42216,612 62.7%   
Fx outflow Rs m1,6785,292 31.7%   
Net fx Rs m8,74411,320 77.2%   
CASH FLOW
From Operations Rs m3,264717 455.5%  
From Investments Rs m-2,093-22,284 9.4%  
From Financial Activity Rs m-1,18629,488 -4.0%  
Net Cashflow Rs m-158,073 -0.2%  

Share Holding

Indian Promoters % 73.8 27.7 266.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 37.8 4.1%  
FIIs % 7.6 8.6 88.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 25.9 65.6%  
Shareholders   20,968 56,241 37.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 21, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS